Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

35.58 +0.75 (+2.15%)
Streaming Delayed Price Updated: 2:10 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now
These cheap stocks are trading at highly attractive prices and have the potential to break through this year. 
Via InvestorPlace
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
The Sunday File for Nov. 21
Good news and bad - making up for the short week by getting a Sunday start. 
Via Talk Markets
Analyst Ratings For Exelixis
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ: 
Via Benzinga
Exelixis Elects Jacqueline Wright to Its Board of Directors
From Exelixis, Inc.
Via Business Wire
Uncertain Times
The UK inflation rate last month was 5.1%, not a good omen. 
Via Talk Markets
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
From Exelixis, Inc.
Via Business Wire
3 No-Brainer Biotech Stocks to Buy in November
Here are three Motley Fool contributors' top picks. 
Via The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
From Exelixis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis: Q3 Earnings Insights
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis... 
Via Benzinga
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Here's My Top Value Stock To Buy Right Now
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
Down 76%: Is Cortexyme Stock a Bargain?
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial. 
Via The Motley Fool
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Exelixis, Inc.
Via Business Wire
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
More Chinese Trouble
A day after the consumer price rise there was another price rise for producer markets. 
Via Talk Markets
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
From Exelixis, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS